The US Food and Drug Administration’s conundrum about unlawful but widespread sales of cannabidiols in dietary supplements has continued so long that industry stakeholders may forget agency executives have said Congress could solve the problem more efficiently.
The FDA soon could get what it requested, says the United
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?